Clinical Trials Logo

PNH clinical trials

View clinical trials related to PNH.

Filter by:

NCT ID: NCT02605993 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: January 4, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of multiple intravenous (IV) doses of ravulizumab administered to complement inhibitor treatment-naïve participants with PNH.

NCT ID: NCT02598583 Completed - PNH Clinical Trials

Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Start date: November 12, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple intravenous (IV) doses of ALXN1210 administered to participants with PNH who have not previously been treated with complement inhibitor.

NCT ID: NCT01412047 Completed - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study

Start date: March 2012
Phase: N/A
Study type: Observational

How does long term treatment with Soliris affect HAHA in PNH patients?